Evidence map›Paper›PMID 29465744›Full record

ArticleThe British journal of surgery2018

Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.

R F D van la Parra, A B Tadros, C M Checka, G M Rauch, A Lucci, B D Smith, S Krishnamurthy, V Valero, W T Yang, H M Kuerer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

R F D van la ParraDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
A B TadrosDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
C M CheckaDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
G M RauchDepartment of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
A LucciDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
B D SmithDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
S KrishnamurthyDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
V ValeroDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
W T YangDepartment of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
H M KuererDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundPatients with triple-negative breast cancer (TNBC) and a pathological complete response (pCR) after neoadjuvant chemotherapy may be suitable for non-surgical management. The goal of this study was to identify baseline clinicopathological variables that are associated with residual disease, and to evaluate the effect of neoadjuvant chemotherapy on both the invasive and ductal carcinoma in situ (DCIS) components in TNBC.

methodsPatients with TNBC treated with neoadjuvant chemotherapy followed by surgical resection were identified. Patients with a pCR were compared with those who had residual disease in the breast and/or lymph nodes. Clinicopathological variables were analysed to determine their association with residual disease.

resultsOf the 328 patients, 36·9 per cent had no residual disease and 9·1 per cent had residual DCIS only. Patients with residual disease were more likely to have malignant microcalcifications (P = 0·023) and DCIS on the initial core needle biopsy (CNB) (P = 0·030). Variables independently associated with residual disease included: DCIS on CNB (odds ratio (OR) 2·46; P = 0·022), T2 disease (OR 2·40; P = 0·029), N1 status (OR 2·03; P = 0·030) and low Ki-67 (OR 2·41; P = 0·083). Imaging after neoadjuvant chemotherapy had an accuracy of 71·7 (95 per cent c.i. 66·3 to 76·6) per cent and a negative predictive value of 76·9 (60·7 to 88·9) per cent for identifying residual disease in the breast and lymph nodes. Neoadjuvant chemotherapy did not eradicate the DCIS component in 55 per cent of patients.

conclusionThe presence of microcalcifications on imaging and DCIS on initial CNB are associated with residual disease after neoadjuvant chemotherapy in TNBC. These variables can aid in identifying patients with TNBC suitable for inclusion in trials evaluating non-surgical management after neoadjuvant chemotherapy.

Indexed as

Neoplasm StagingAdultAgedAntineoplastic AgentsCarcinoma, Ductal, BreastChemotherapy, AdjuvantConservative TreatmentFemaleFollow-Up StudiesHumansMiddle AgedNeoadjuvant TherapyProspective StudiesTreatment OutcomeTriple Negative Breast NeoplasmsAntineoplastic Agents

Identifiers

PMID29465744
PMCPMC7938811
OpenAlexW2792983588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.